Reuters: In Fresenius, Danone could lose second suitor for nutrition unit

French company Danone hasn't had much luck so far hawking its medical nutrition business--and bidder Fresenius may be set to walk away, Reuters reports. After talks reportedly stalled with tax inversion-minded Hospira ($HSP), the German drugmaker is now considering pulling out thanks to frustration with a long, complicated sales process. On the other hand, "it would be wrong to say Fresenius is not interested anymore," one source told the news service. Story | More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.